Clinical Edge Journal Scan

Dr Jayatilleke: Risk of fracture in younger patients is less frequently recognized

Dr. Jayatilleke scans the journals, so you don’t have to!

Author and Disclosure Information

 

Arundathi Jayatilleke, MD

Recent studies have highlighted issues with potential impact on women with RA. In many rheumatic diseases, achieving control of disease activity (i.e., a low disease activity state) predicts better outcomes in pregnant patients; those who have higher disease activity are at risk for adverse outcomes such as low birth weight. Smeele et al examine use of a modified treat-to-target (T2T) approach in patients prior to and during pregnancy. 184 patients were treated preferentially with hydroxychloroquine and sulfasalazine, with prednisone and certolizumab added if needed to achieve low disease activity or remission; patients who were on a TNF inhibitor were allowed to continue and then switched to certolizumab or discontinued in the third trimester. Overall, most patients (90%) were able to achieve low disease activity. About half reached low disease activity without a TNF inhibitor, and no difference in disease activity in patients who switched vs. stopped TNF inhibitor treatment and those who stopped, though as the authors point out, TNF inhibitors were only stopped in those patients in remission. Analysis of the subset of patients in the cohort who did not have RA was unclear.


Salliot et al examine the relationship between female sex hormone exposure and risk of RA in a large cohort of French women. Based on a biannual questionnaire, 698 RA cases were diagnosed among 78,452 women and examined for association with endogenous and exogenous sex hormone exposure (e.g., age at menarche, parity, age at menopause, use of oral contraceptives, and use of hormone replacement therapy). Early age at menopause (≤45 vs >53 years) and early age at first pregnancy (<22 vs ≥27 years) were associated with increased risk of incident RA. Among exogenous hormone exposure, duration of perimenopausal progestogen use >24 months was inversely associated with risk of RA (HR 0.77). The results of this study are difficult to fit into a simple narrative regarding cumulative hormonal exposure or lifetime reproductive events, and the hazard ratios in question are relatively low. Even taking into account the fact that the study only looked at RA incidence after menopause, a larger cohort size may be necessary to determine whether type and timing of hormone exposure influences RA risk.

New biomarkers remain of high interest in RA in order to better predict severity and tailor treatment. ACPA positivity is known to be associated with joint damage in RA; however, ACPA-negative RA patients have similar outcomes in terms of pain and fatigue. Lamachia et al analyze the predictive value of anti-carbamylated protein (anti-CarP) and anti-peptidyl-arginine deiminase type-3 (anti-PAD3) antibodies in identifying patients at risk of severe RA outcomes. Anti-PAD3, but not anti-CarP, positivity was associated with higher baseline swollen joint counts and DAS28-ESR, as well as higher overall disease activity and joint damage scores, but not radiographic progression. While there was significant overlap between RF- and ACPA-positive and anti-PAD3 positive RA patients, the existence of a subset of nearly 20% of anti-PAD3 positive patients who were anti-CCP3 negative suggests that anti-PAD3 could have diagnostic in addition to predictive utility.

In addition to risk of joint damage, people with RA also have an increased risk of fracture due to low bone density, glucocorticoid use, and other factors. While we may recognize this in older patients, the risk in younger patients may be less frequently recognized. In this retrospective cohort study, Erwin et al examined risk of fracture and risk of first fracture before age 50 in RA patients compared to matched controls. Overall, fracture risk was higher in RA patients even after adjusting for age at diagnosis, gender, glucocorticoid risk, smoking, and alcohol use. Women in particular had a higher risk of first fracture before age 50 compared to women without RA; men did not have a similar risk. Hopefully awareness of this increased risk among younger RA patients will lead to better preventative strategies as well.

Recommended Reading

Filgotinib+MTX shows benefit in RA patients with inadequate response to MTX
MDedge Rheumatology
Anti-PAD3 positivity tied to higher disease activity and joint damage in RA
MDedge Rheumatology
Safety and efficacy of biosimilar CT-P17 and adalimumab in RA
MDedge Rheumatology
Modern treatment approach results in LDA and remission in pregnant patients with RA
MDedge Rheumatology
Impact of female hormonal exposure on risk of RA
MDedge Rheumatology
Younger RA patients at greater fracture risk even before age 50 years
MDedge Rheumatology
Anti-TNF responding RA: Tocilizumab bests rituximab in reducing disease activity
MDedge Rheumatology
Nonsurgical periodontal treatment could improve disease activity in RA patients with periodontitis
MDedge Rheumatology
MRI-detected tenosynovitis can predict early RA
MDedge Rheumatology
Rheumatoid arthritis linked to risk for peritonsillar abscess
MDedge Rheumatology